Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
Trial Parameters
Brief Summary
To evaluate the efficacy and safety of chidamide combined with brentuximab vedotin regimen for CD30 positive PTCL patients who are unfit for chemotherapy.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥70 years or age \< 70 years and unfit for chemotherapy, male or female not limited; 2. Patients must have the capacity to understand and willingly provide written informed consent; 3. ECOG score 0-3 points; 4. Expected lifespan\>3 months; 5. Patients with CD30+ peripheral T-cell lymphoma (PTCL) confirmed by histopathology/cytology using the 2022 World Health Organization (WHO) Classification of Diseases; 6. Measurable lesions with a short diameter of ≥15mm defined by PET/CT. 7. R/R PTCL: patients with at least previous first-line treatment failure and no prior exposure to chidamide and brentuximab vedotin. 8. Patients are unfit for chemotherapy after evaluation or are not considered for chemotherapy for other reasons; 9. Any non-hematological toxicity, except hair loss, associated with prior treatment in patients with R/R disease, as per NCI CTCAE version 5.0, must be managed and resolved to at least grade 1; 10. Appropriate organ function: Cardiac function: